The Pittsburgh Institute for Multiple Sclerosis care is pleased to announce that it has been chosen as an enrolling site in the NN102 SPRINT-MS: “A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability and Activity of Ibudilast (MN-166) in Subjects with Progressive Multiple Sclerosis.” This study has met its target enrollment and is no longer recruiting participants. Read more.